Humacyte is cutting costs to conserve cash as it tries to build momentum for its new product. But its stock is down more than 60 percent this year.
https://www.bizjournals.com/triangle/news/2025/05/14/humacyte-layoffs-expenses-cost-stock-huma-fda.html